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Introduction
Horizons in Medicine is a series produced annually by the Royal College of Physicians.1 
Volume 19 is based on their Advanced Medicine Conference held in 2007 and certainly 
constitutes a tour de force of major advances in clinical medicine. It provides essential 
updated information pertaining to a wide range of different medical specialties and 
interests, and in the process touches on a mix of cutting edge scientific and clinical 
developments. The topics covered in each of the diverse chapters should be of some 
interest to the relevant specialists, but are even more likely to excite doctors and others 
not working in that particular field. Moreover, changes in medical understanding and 
practice occur very rapidly, and there is an increasing overlap between disciplines. Thus, 
whether in advanced or less developed countries, the contents could well provide eye-
openers for medical students, trainee physicians, general practitioners and consultants, 
whatever their specialty. In a book of just under 400 pages, the expert contributors cannot 
cover all advances in their respective fields comprehensively, however, areas as diverse as 
radiology and imaging, respiratory medicine, renal disease, rheumatology, and neurology 
get relatively generous airings. Finally, readers of this ‘review of reviews’ of practical and 
theoretical aspects of general medicine, should appreciate that in an article of this size it 
was only feasible to cover a selection of the chapters. No doubt these reflect the biases of 
this particular reviewer. Moreover, the topics referred to in each of the items captioned 
below correspond to chapters and are only summaries that are not referenced. Interested 
persons can consult Horizons in Medicine 19 directly for appropriate details, including 
references.
Contemporary management of acute myocardial infarction
This chapter concentrates on acute ST elevation myocardial infarction (STEMI), a topic 
with practical implications for many doctors and a large proportion of the general public. 
Based on the widely accepted premise that early establishment of an ‘open artery’ improves 
short- and long-term outcomes and symptoms, the author sets out the pros and cons of 
thrombolysis versus percutaneous coronary intervention (PCI) including stenting. Key 
observations include that: (i) fibrinolysis within 12 hours of symptoms reduces the 35-
day mortality from about 13 to 8-9%; (ii) the earlier the treatment the better the outcome, 
irrespective of age, gender, prior hypertension or diabetes; and (iii) intervening after 12 
hours confers uncertain benefit. It is noted that the fibrin-specific agents, such as tissue-
type plasminogen activator achieve patent vessels in about 70% of patients compared to 
about 35% following streptokinase administration, with a small corresponding benefit in 
terms of mortality (6.3 vs 7.3%), but a slight excess in strokes. Thus, fibrin-specific agents 
are increasingly favoured for thrombolytic reperfusion of STEMI. Several studies indicate 
inferior long-term benefits with the former, particularly if good flow rates are not achieved. 
For this reason, adjunctive anti-platelet agents (aspirin or clopidogrel) are suggested as 
one option to augment vessel patency and may well become standard practice. A further 
limitation of thrombolysis was late re-occlusion (ensuing within 3 months) in up to 30% 
of patients, especially in poorly perfused vessels. Recognition that early reperfusion 
(within 70 minutes of pain onset) is critical, has led to pre-hospital thrombolysis being 
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administered by paramedics. Several studies reported 
that this strategy conferred significantly improved 
pain resolution and superior outcomes. One trial 
revealed an improved trend for all cause mortality 
(9.7 vs 11.1%), and significantly improved cardiac 
mortality (8.3 vs 9.8%), and a meta-analysis of six trials 
also showed consistent benefits. Compared to PCI, 
the key advantages of thrombolysis were that it is, 
safe, easily administered and likely to be available in 
the facilities that patients are likely to use.
 Several studies indicated that PCI (balloon 
angioplasty and stenting) on presentation (within 3 
hours of onset) conferred a highly significant absolute 
benefit compared to ‘optimal’ thrombolysis, both in 
terms of short-term mortality and reinfarction, and 
less-frequent late re-occlusions. These studies had 
several critical shortcomings, however, including 
small patient numbers (wide confidence intervals) 
and comparisons only with hospital thrombolysis 
controls. Moreover, the logistics of providing 
highly trained intervention teams round-the-clock 
and within easy reach of the majority of patients is 
daunting. Options to overcome these challenges 
include: thrombolysis facilitated by PCI; more 
intervention centres; patients being transferred from 
or bypassing non-intervention centres. The latter 
strategies have been criticised as being expensive, 
largely untested or of no benefit, and liable to pose 
major logistic problems.
 Thus early thrombolysis still appears to be the 
most feasible option for most patients, and, if it fails, 
early rescue PCI is a reasonable compromise. Even 
if thrombolysis is successful, pre-discharge follow-
up PCI (if indicated) appears a sensible course of 
action.
Imported infectious disease emergencies
This is a useful and informative topic, not only 
for specialists in infectious disease, emergency 
medicine, and intensive care physicians, but also for 
other doctors and the public. The subject matter is 
particularly germane in this era of globalised business, 
educational travel, non-governmental organisation 
activities, and exotic tourist destinations.
 Key points are made through the use of case 
histories. Crucial information to glean from a travel 
history and some useful web addresses are also 
provided. The discussion of rabies lacks immediacy, 
however, there being no mention of risk conferred by 
licks from feral dogs, and post-exposure prophylaxis 
(a practical option) is given no greater importance 
than pre-exposure prophylaxis.
Update on HIV
HIV infection used to be relentlessly progressive and 
fatal in most cases. Yet within the last 25 years, and 
largely due to unparalleled global commitments, it 
can now be regarded as a chronic, stable condition 
(if appropriately treated). Several challenges 
remain, however. Principally due to an explosion 
in heterosexual transmission, about 30% of those 
afflicted are unaware of their condition, forming 
a large reservoir of occult infectors. This results in 
late diagnosis when the disease is less amenable to 
effective treatment. In many parts of the world, co-
infection with rapidly progressive tuberculosis (TB) 
is becoming the leading cause of death and also, 
possibly, of AIDS-defining illnesses. HIV testing is 
therefore being routinely recommended in patients 
aged 15 to 64 years with newly diagnosed TB. 
Such TB is frequently atypical (extrapulmonary or 
disseminated). Sometimes (particularly in Africa), it is 
resistant to first- and many second-line anti-TB drugs 
and is therefore referred to as extensively drug-
resistant TB (XDR-TB). Transmission of XDR-TB to the 
general population obviously poses a major problem, 
requiring new global initiatives.
 Highly active anti-retroviral therapy (HAART) 
consists of treatment with various combinations of 
nucleoside and non-nucleoside reverse transcriptase 
inhibitors and protease inhibitors. Each of these drugs 
has its own propensity to a variety of adverse reactions 
(eg lipoatrophy, heart disease). Moreover, as treatment 
regimens become safer, earlier initiation of HAART is 
increasingly recommended; the threshold for starting 
therapy has shifted from CD4 lymphocyte counts of 
<200 towards <350 mm3. Newer and, hopefully, safer 
and more effective classes of anti-HIV drugs (fusion 
inhibitors, integrase inhibitors, and others) are under 
development. The advantages of earlier treatment 
(preserved immunity, decreased risk of transmission, 
prolonged disease-free survival, fewer adverse events, 
reduced mortality) are believed to outweigh the 
disadvantages (various drug toxicities, development 
of drug resistance, exhaustion of options). Strategies 
for HIV prevention that appear to work are: education 
(abstinence, condoms); preventing peripartum 
mother-to-child infection using anti-retroviral drug 
combinations for both parties, elective caesarian 
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delivery, avoiding breastfeeding; male circumcision; 
and post-exposure prophylaxis (eg after needlestick 
injuries and perhaps after risky sexual exposure). 
Finally, a trend towards HIV testing being offered 
more readily is highlighted, along with the possibility 
of removing the current requirements for counselling 
and written informed consent.
Highly pathogenic avian influenza H5N1 
in humans
This still rare form of influenza is covered in the 
context of influenza in general. The author rightly 
points out that preparing for a pandemic due to the 
virus becoming capable of transmission from human 
to human is fraught with uncertainty. The premise on 
which current recommendations are based and the 
potential waste of resources and effort are questioned, 
especially as the next influenza pandemic could just 
as easily entail entirely different virus serotypes.
New therapies in the management of 
type 2 diabetes
This discussion concentrates on newer glucose-
lowering strategies and drugs developed in 2006 
and 2007. As background, cannabinoids injected 
into the hypothalamus of animals stimulate feeding 
and weight gain, whilst knock-out or blockade of 
the corresponding receptors has converse effects. 
Several clinical trials have reported using rimonabant 
(a cannabinoid receptor blocker) in patients with type 
2 diabetes. These confirmed that treated patients lose 
weight, and have lower levels of fasting glucose and 
HbA1c (by 0.7%). This treatment also improved features 
of the metabolic syndrome, including dyslipidaemia 
and abdominal adiposity, but many patients developed 
nausea and/or mood disturbance (depression and 
anxiety), effects predictable from the opposing effects 
of cannabis on mood. These symptoms contributed 
to high discontinuation rates with this therapy. 
Another approach involves enhancement of so-
called ‘incretin’ activity. This refers to the observation 
that the insulin level increments seen in response 
to a meal far exceed those produced by intravenous 
infusion of equivalent amounts of glucose. Thus, 
feeding appears to stimulate insulin secretion 
additional to that induced by increased circulating 
glucose concentrations alone, for which gut derived 
peptides (including GLP-1) appear responsible. 
Patients with type 2 diabetes produce less GLP-1, 
which normally helps to reduce postprandial glucose 
levels via increased insulin secretion and decreased 
glucagon release. This peptide is rapidly degraded by 
endothelial receptors, and must be given parenterally 
(not by mouth). Exenetide, a currently marketed GLP-
1 mimetic (derived from lizards) is much more potent 
than the human variety, and much more resistant to 
degradation by the corresponding human enzyme 
DPP-4. Evidently, daily exenetide injections and use 
of the DPP-4 inhibitors sitagliptin and vildaglitin 
are currently being investigated in humans as aids 
to the treatment of type 2 diabetes. Both options 
are reported to be relatively safe, in the short term 
at least. How these new forms of drug treatment 
(cannabinoid receptor blockers, GLP-1 mimetics, and 
DPP-4 inhibitors) will fit into overall drug treatment 
for type 2 diabetes remains to be seen.
Management of adrenal insufficiency in 
severe stress and surgery
Stress and adrenal insufficiency is discussed with 
respect to the role of glucocorticoids, not only 
in the presence of primary or secondary adrenal 
insufficiency but also in subjects not known to have 
defective adrenal function (but possibly exhibiting 
relative deficiency). The relevant stress could be 
physical (due to surgery or trauma), or emotional 
(social). Moreover, the acute adrenal insufficiency 
could manifest as a ‘shut down’ akin to hypovolaemic 
shock, or as a vasodilated hyperdynamic state 
resembling ‘septic’ shock, depending on preserved 
mineralocorticoid secretion and attempted prior fluid 
resuscitation. Notably, for critical illnesses in patients 
not previously known to have adrenal deficiency, some 
evidence favours the use of low-dose supplementary 
steroids, even though basing decisions to intervene 
on the results of short Synacthin tests, is debatable. 
The aptly named ‘CORTICUS’ trial,2 that was published 
after Volume 19 of Horizons in Medicine, showed no 
benefits from steroids and therefore sheds further 
light on these issues.
Making sense of ‘funny thyroid function 
tests’
This is a must-read for every general physician. Total 
thyroxine (T4) and total triiodothyronine (T3) levels 
can be misleadingly high in euthyroid patients, due to 
elevated levels of thyroid binding globulin, prealbumin 
and albumin (in pregnancy, after oestrogen intake, and 
in hepatic disorders). Thus, modern clinical laboratories 
should be able to measure free thyroxine (FT4) and free 
tri-iodothyronine (FT3) levels, in addition to offering a 
highly sensitive assay for thyroid stimulating hormone 
(TSH). The author points out that claims that patients 
have genuine hypothyroidism (warranting treatment), 
despite all three of the latter test results being 
within normal limits, are untenable. Exceptionally, T4 
replacement therapy for hypothyroidism restores TSH 
to normal but with low-normal FT4 and FT3 levels; 
ideally such patients (having a reset feedback axis) 
need TSH levels to be high-normal. Divergent (funny) 
test results referred to include: (i) low TSH with normal 
FT4 and/or FT3 levels; (ii) vice versa; (iii) high TSH but 
normal FT4 and/or FT3 levels; or (iv) vice versa.
 Numerous possible causes for each set of 
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these possibilities (including pituitary disorder, drug 
effects, and non-thyroid disease) are itemised and 
discussed.
The modern management of chronic 
myeloid leukaemia
This myeloproliferative disorder caused by a 
consistent chromosomal translocation (the 
Philadelphia chromosome), results in dysregulated 
tyrosine kinase activity and a characteristic leukaemic 
proliferation. Hitherto, the treatment of choice for 
all eligible patients has been allogenic stem-cell 
transplantation (the only curative treatment), so 
long as suitable matched donor cells were available. 
For all others, a-interferon-based treatment and 
simple cytoreduction were used. Now, however, the 
tyrosine kinase inhibitor (TKI) imatinib has become 
the preferred treatment over all other previously 
available alternatives. A pivotal phase III study showed 
markedly superior rates of complete haematological 
remission and cytogenetic response (95 and 94% vs 55 
and 8%) and progression-free survival at 18 months 
(97 vs 92%) compared to older forms of treatment. 
Nevertheless, in a small minority of patients, imatinib 
therapy continues to pose problems, including 
failure to respond, loss of responsiveness, resistance 
(related to mutations and other factors), and disease 
acceleration and blast crisis. Options to overcome 
these problems include dose escalation, use of 
alternative newer TKIs, and reversion to older forms 
of chemotherapy.
Myeloproliferative disorders: 
management and molecular pathogenesis
This deals with polycythaemia vera (PV) and essential 
thrombocytosis (ET). In PV, according to the efficacy 
and safety of low-dose aspirin in polycythaemia vera 
(ECLAP) study, aspirin significantly reduced the risk 
of the combined primary endpoint (fatal and non-
fatal stroke or myocardial infarction, pulmonary 
embolism, major venous thrombosis, or death from 
cardiovascular disease). Further analysis indicated 
that all PV groups showed benefit, independent of 
disease duration, cytoreduction therapy, and blood 
counts at trial entry. The fact that this trial did not 
entail a factorial design (aspirin versus placebo, 
and cytoreduction versus phlebotomy) is not made 
clear by the reviewer. Moreover, patients for whom 
aspirin was clearly indicated were excluded per 
protocol (n=742); yet out of the remainder that were 
randomised (n=518), why would up to 5% who had 
experienced a prior arterial thrombosis not have had 
an indication for aspirin? Regarding ET, a Medical 
Research Council trial of more than 800 patients 
(aged >60 years) with a prior thrombosis or platelet 
count >1000x109 /L showed clear benefits for those 
randomised to hydroxyurea plus aspirin rather 
than anagrelide plus aspirin. In the former group 
the benefits extended to reduced rates of arterial 
thrombosis, major haemorrhage, myelofibrotic 
transformation (diagnosed by trephine biopsy), and 
treatment withdrawal; only venous thromboembolism 
was more common. Whether hydroxyurea protects 
against myelofibrotic transformation or anagrelide 
increases the risk remains unclear on the basis of this 
trial.
 The discovery of a single acquired point 
mutation in the JAK2 gene of haemopoietic stem cells 
in nearly all patients with PV and about half those 
with ET has important implications, since this genetic 
change appears to dysregulate tyrosine kinase 
activity and erythrocytosis. Moreover, JAK2 mutation 
negative ET patients do not become positive for the 
mutation over time, indicating that there are two 
distinct forms of ET, one of which overlaps with PV. 
This finding raises the possibility of new approaches 
to the diagnosis, classification and treatment of these 
diseases.
Drug allergies
These are evidently the most important cause of 
type B adverse drug reactions (idiosyncratic, not 
predictable from pharmacological properties, and 
having no obvious relation to dosage), and are mainly 
immunological. Non-immunologic (ie chemical) 
type B reactions (eg dapsone-induced neuropathy, 
azathioprine-induced marrow suppression) are 
also noted, but only occur in very few susceptible 
individuals. Drug hypersensitivity linked to 
underlying immune mechanisms depends on drug-
protein combinations (haptenes) being recognised 
as ‘non-self’ by receptors on T-cells, and have been 
classified into four types.
Type I
Type I (immediate or late) hypersensitivity reactions 
involve immunoglobulin (Ig) E antibodies bound to 
mast cells and basophils. Corresponding antigens 
reaching and combining with relevant antibodies 
release histamine, other vasoactive mediators, and 
eosinophil and neutrophil chemotactic factors. 
Characteristic type I reactions are: asthma, urticaria 
(weals lasting only a few hours), angioedema, and 
anaphylaxis. These reactions occur within 15 minutes, 
or 6 to 24 hours after exposure to the relevant drug, so 
long as drug exposure continues for more than 7 days 
or there has been prior exposure. Such IgE mediated 
type I reactions are often due to antibiotics (especially 
penicillins), or anaesthetic agents, including muscle 
relaxants. There are identical reactions (eg to non-
steroidal anti-inflammatory drugs [NSAIDs], opiates, 
and muscle relaxants) termed ‘pseudoallergic’ (or 
anaphylactoid), because no immune mechanisms 
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have been demonstrated and they seem to occur 
without a 7-day latent period. About 1 in 10 000 
courses of penicillin are noted to result in reactions 
resembling anaphylaxis, about half of which may be 
pseudoallergic.
Type II
Type II reactions entail antigenic determinants on 
cell surfaces, which are targeted by circulating IgG or 
IgM; after binding these immunoglobulins activate 
the complement cascade, leading to cytotoxicity. 
Such toxicity includes: (i) drug-dependent pemphigus 
that regresses after discontinuation of treatment (eg 
due to penicillamine and captopril); and (ii) drug-
triggered (true) pemphigus (eg due to penicillins, 
cephalosporins, and piroxicam) that then follows its 
normal natural history, even after drug withdrawal.
Type III
Type III reactions are caused by circulating immune 
complexes (antigen-IgE/IgM) depositing in vessel 
walls. About 8 to 10 days after drug exposure these 
give rise to a variably persistent vasculitis in skin and 
elsewhere (via complement cascade activation). A 
wide range of agents (antibiotics, NSAIDs, cytotoxics) 
may be responsible.
Type IV
Type IV (delayed, T-cell mediated) hypersensitivity 
takes around 48 hours to evolve and may be systemic, 
or topical (manifesting as indurated contact dermatitis 
or eczema). The latter reactions are commonly due 
to topical antibiotics, antiseptics, local anaesthetics 
and even corticosteroids. Among others, systemic 
reactions include: maculopapular eruptions, toxic 
erythemas, and the increasingly serious reactions 
termed erythema multiforme (EM), toxic epidermal 
necrolysis (TEN), and Stevens-Johnson syndrome (SJS). 
These rashes are often due to anticonvulsants, allo-
purinol, NSAIDs and antibiotics; the maculopapular 
eruptions can be diverse, and include urticarial weals 
that last several days. In contrast, urticaria due to type 
I reactions only lasts up to 12 hours. Characteristically, 
EM, TEN and SJS manifest ‘target’ lesions (that blister), 
particularly around muco-cutaneous junctions. The 
reactions seem to involve CD4 and CD8 T-lymphocyte 
mediated apoptosis, are associated with systemic 
features (fever, tachycardia, lymphadenopathy, renal 
and liver dysfunction, haematological abnormalities) 
and have a high mortality (30% or more). Regarding 
management, apart from withdrawal of the offending 
drug, corticosteroids and immunosuppressive 
agents are advocated. The role of early intravenous Ig 
remains controversial. If causality is not established, a 
meticulous chronology of the drug history can help. 
A variety of in-vitro and in-vivo tests are available 
but are not consistently useful, and some are not 
applicable during or soon after an acute reaction.
Osteoporosis
Osteoporosis and its consequential fractures (mainly 
hip, wrist and vertebral) are increasingly important 
direct and indirect causes of morbidity, mortality 
and health care costs. In both developed and 
developing countries, osteoporosis is largely due 
to an increasingly aged population and sedentary 
lifestyles. Hypogonadism, malabsorption, endocrine 
disorders, immobility, chronic renal or liver failure, 
and treatment with certain drugs (glucocorticoids, 
aromatase inhibitors) predispose to this condition 
(defined by bone densitometry). Other major factors 
associated with corresponding fractures, some of 
which are preventable, include: old age, previous 
fragility fractures (especially hip), smoking, alcohol 
abuse, rheumatoid arthritis, low body mass index, 
and falls. Several pharmacological interventions have 
now been approved for osteoporosis prevention, 
though the optimal length of treatment is unclear and 
compliance is often unsatisfactory. Bisphosphonates 
(eg alendronate) are the first-line drugs, taken orally 
(and rarely intravenously). Precautions listed to avoid 
upper gastro-intestinal (oesophageal) symptoms 
include: taking them while standing or sitting up, 
with a full glass of water, and in the morning. In 
the very elderly, strontium ranelate is another 
first-line agent taken orally once a day. It increases 
spine and hip bone mineral density (by yet-to-be 
defined mechanisms); diarrhoea, nausea, headache 
and venous thromboembolism are infrequently 
associated adverse effects. Raloxifene (a selective 
oestrogen receptor modulator) taken orally once a 
day, is a second-line option; leg oedema and cramps, 
hot flushes and venous thromboembolism are its 
adverse effects, whereas the risk of breast cancer 
appears reduced. Parathormone (also a second-
line agent) is very costly and usually reserved for 
patients intolerant of alternatives, or those with 
severe vertebral osteoporosis. Due to its perceived 
unfavourable risk-benefit balance, hormone 
replacement therapy is also deemed a second-
line treatment, often restricted to the treatment of 
younger post-menopausal women at high risk of 
fracture, especially those with vasomotor symptoms. 
Calcium and vitamin D are not regarded as evidence-
based treatments able to counter osteoporosis.
New biologics for rheumatoid arthritis
Rheumatoid arthritis is an important cause of disability 
and premature death (from cardiovascular causes, 
malignancy and infections), and its management has 
undergone a paradigm shift. Based on randomised 
clinical trials in thousands of patients, early diagnosis 
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and early intervention with disease-modifying 
anti-rheumatic drugs (DMARDs) usually involving 
methotrexate, have proved highly efficacious and 
become the norm. If necessary, biologically targeted 
agents are added to these regimens, and may 
arrest/minimise clinical and radiological disease 
progression. That the highly specific marker anti-
cyclic citrullinated peptide antibody has a possible 
role in the pathogenesis of rheumatoid arthritis is 
discussed, though there is no mention of testing 
for it to augment early diagnosis of the disease. 
Biologically targeted constituents in DMARD 
regimens include tumour necrosis factor (TNF) 
blockers (infliximab, etanercept, adalimumab) given 
as courses of injections over several weeks. These 
appear to confer dramatic benefits in some patients, 
but may also manifest important toxicities (local 
reactions, long-term risk of TB, and possibly increased 
risk of malignancy and heart failure) that should be 
vigilantly anticipated. Rituximab (a monoclonal B-
lymphocyte depleting antibody) infusions are also 
being used as a component of DMARD therapy. The 
latter combinations counteract antibody-mediated 
cytotoxicity, and often relieve symptoms, even in 
patients for whom anti-TNF treatments have failed. 
Apart from hypersensitivity reactions, other forms of 
clinical toxicity have not been reported to date.
Understanding migraine from bench to 
bedside
This is taken from the Croonian Lecture given by 
Peter Goadsby, and draws attention to aspects of this 
common condition that many doctors are not aware 
of. Whilst migraine is commonly familial (hereditary), 
about 50% of such patients have the variety known as 
familial hemiplegic migraine that is linked to specific 
ion channel gene mutations on chromosome 19. 
These mutations may be related to the aura process 
that in animal models at least, reduces the threshold 
for ‘cortical spreading depression’. Only in the latter 
families, attacks can be triggered by minor trauma, 
can result in coma, and can have associated cerebellar 
ataxia. Exactly how the migraine aura fits into the 
pathogenesis of the headache remains unclear. Most 
individuals with classical migraine headache have 
no aura, whereas others often have aura without 
headache. Aura suppression by ketamine does not 
abort the headache, and ‘aura’ can ensue during or 
after the headache, as well as with other headache 
types.
 Based on animal and human studies, it is 
proposed that small myelinated and non-myelinated 
fibres of the trigeminal ganglion and upper cervical 
routes that innervate cerebral, pial, and dural vessels 
have a role in pain perception from these structures. 
Pain-producing substance, calcitonin, and plasma 
protein extravasation may also be involved. Whatever 
actually transpires during a migraine attack, episodic, 
central nervous sensory sensitisation seems to be 
a key feature, such that ordinarily non-noxious 
stimuli (sound, light, even odours, and sometimes 
head movements) become uncomfortable and 
associated with throbbing pain in the head. Merely 
being touched ipsilaterally and/or contralaterally can 
produce pain (allodynia).
